BioSpace News Archive

PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin.

Summit Therapeutics Inc. announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024.

Kyverna Therapeutics, Inc. (Nasdaq: KYTX) announced today its attendance at the 2024 annual meeting of the American Academy of Neurology to be held in Denver, Colorado, starting on April 13.

Longeveron Inc. announced the closing of its previously announced public offering of up to 2,234,043 shares of the Company’s Class A common stock and warrants to purchase up to 2,234,043 shares of Class A common stock at a combined offering price of $2.35 per share and associated warrant.

Oncocyte Corporation, a precision diagnostics company, announced that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.9164 per share of common stock, and pre-funded warrants to purchase 342,888 shares of common stock at a purchase price of $2.9163 per pre-funded warrant.

Rakuten Medical, Inc. announced a poster presentation of its study to manage edema following photoimmunotherapy at the 115th Annual Meeting of the American Association for Cancer Research in San Diego, California, on April 8th, 2024.

Orca Bio today announced new data will be presented during the 50th Annual Meeting of the EBMT in Glasgow, United Kingdom.

Neurelis, Inc. will present a poster on VALTOCO® (diazepam nasal spray) for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in patients with epilepsy ages 6 to 65 years, describing the time to treatment across different subpopulations.

BLR Bio, an emerging biotechnology company in Rosalind Franklin University’s Helix 51 biomedical incubator, announced that the U.S. Food and Drug Administration (FDA)